Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big Pharma is facing a looming $236 Billion patent cliff

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Jun 08, 2022 2:47pm

126 Views

Post# 34741212

RE:RE:RE:RE:RE:RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliff

Hello Norm and not trying to be doubtful, all I was doing was letting people know was that your patent count was wrong and we now have about 150 less patents just from the information that you posted. Nothing wrong with updating people with the correct information. I too am just hoping that all of our patents are in place if we get approval and Matt said the same thing in the recent conference...My guess is that we will most likely be bought out by then anyway so will not have to worry, but it is nice to keep people informed of the proper information that is out there.

<< Previous

Bullboard Posts

Next >>

Nord Precious Metals reveals silver zone at Castle East